£810 / $1295 / €985
The cooling economic environment and the weakening lira has moderated optimistic forecasts on the Turkish pharmaceutical market, especially as the government is the single largest reimburser of pharmaceuticals, covering 80-85% of total drug expenditure through various insurance and immunisation schemes. Price cutting and public discount decrees announced in November 2011 continue to affect the pharmaceutical market in 2012, as highlighted by the decrease in pharmaceutical spending in the first half of this year.
Headline Expenditure Projections
Pharmaceuticals: TRY17.21bn (US$10.24bn) in 2011 to TRY16.35bn (US$9.03bn) in 2012; -5.0% in local currency terms and -11.8% in US dollar terms. Local currency forecast downgraded from Q 4 12 on account of H112 data .
Healthcare: TRY83.59bn (US$49.75bn) in 2011 to TRY92.02bn (US$50.84bn) in 2012; +10.1% in local currency terms and +2.2%in US dollar terms. Local currency forecast slightly increased from Q 4 12 due to increased healthcare investment .
Medical devices: TRY4.33bn (US$2.58bn) in 2011 to TRY4.78bn (US$2.64bn) in 2012; +10.3% in local currency terms and +2.4% in US dollar terms. Local currency forecast broadly unchanged from Q 4 12.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.